Biotech startups that raised Series A in Palo Alto, United States
Updated 16 Nov 2026
Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Company | City | Last round | Amount | Date |
|---|---|---|---|---|
| ImpriMed | Palo Alto | Series A | $10.0M | 2026-09-18 |
| TwoStep Therapeutics | Palo Alto | Series A | $62.5M | 2026-09-09 |
| Transcripta Bio | Palo Alto | Series A | $24.0M | 2026-07-22 |
| Biostate AI | Palo Alto | Series A | $12.0M | 2025-05-20 |
| Inceptive | Palo Alto | Series A | $100.0M | 2023-09-07 |
| Ganymede | Palo Alto | Series A | $12.8M | 2022-08-09 |
| The Public Health Company | Palo Alto | Series A | $35.0M | 2022-05-01 |
| Artificial | Palo Alto | Series A | $21.5M | 2021-05-18 |
8 rows of the CSV in 5 of its 18 columns.
- The 34 biotech startups in Palo Alto, United States whose last round is Series A have raised $1.6B in total.
- 8 of them closed their most recent round in the last 12 months, $407.5M combined.
- The largest of those rounds is AirNexis Therapeutics' $200.0M Series A, dated January 2026.
- The most recent is ImpriMed's $10.0M Series A on 18 September 2026.
- AME Cloud Ventures is an investor in 2 of them, more than any other fund.
- Health care is the most common other sector, with 29 companies (85%).
- 50% were founded in 2020 or later; the median founding year is 2020.
- The most common team size is 11 to 50 employees (69% of companies with a recorded size).
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Newest rounds
3 of 34| Company | What they do | Sector | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|
| ImpriMed | ImpriMed provides AI-driven precision medicine services to oncologists and pharmaceutical companies. | Artificial intelligence | Series A | $10.0M | 2026-09-18 | $44.7M | Plug and Play, Pear VC, Draper Associates +1 | 51 to 100 | 2017 |
| TwoStep Therapeutics | TwoStep Therapeutics develops tumor-targeting therapeutics for solid tumors. | Biotech | Series A | $62.5M | 2026-09-09 | $90.1M | NFX, 2048 Ventures, Alexandria Venture Investments +1 | 11 to 50 | 2023 |
| Transcripta Bio | Transcripta Bio develops drugs at an accelerated pace with reduced risk. | Biotech | Series A | $24.0M | 2026-07-22 | $34.4M | BlueYard Capital, Jazz Venture Partners | 11 to 50 | 2020 |
Table 1. Biotech startups that raised Series A in Palo Alto, United States: the 3 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 34.
Largest rounds
Last 12 months| # | Company | What they do | Sector | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | TwoStep Therapeutics | TwoStep Therapeutics develops tumor-targeting therapeutics for solid tumors. | Biotech | Series A | $62.5M | 2026-09-09 | $90.1M | NFX, 2048 Ventures, Alexandria Venture Investments +1 | 11 to 50 | 2023 |
| 2 | Transcripta Bio | Transcripta Bio develops drugs at an accelerated pace with reduced risk. | Biotech | Series A | $24.0M | 2026-07-22 | $34.4M | BlueYard Capital, Jazz Venture Partners | 11 to 50 | 2020 |
| 3 | ImpriMed | ImpriMed provides AI-driven precision medicine services to oncologists and pharmaceutical companies. | Artificial intelligence | Series A | $10.0M | 2026-09-18 | $44.7M | Plug and Play, Pear VC, Draper Associates +1 | 51 to 100 | 2017 |
Table 2. Biotech startups that raised Series A in Palo Alto, United States: the 3 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most active investors
By companies backed| # | Investor | Type | Location | Companies | Share | Funded, 12 months | Latest |
|---|---|---|---|---|---|---|---|
| 1 | AME Cloud Ventures | Venture capital firm | Palo Alto, United States | 2 | 6% | ||
| 2 | Draper Associates | Venture capital firm | San Mateo, United States | 1 | 3% | 1 | ImpriMed |
| 3 | Murex Partners | Venture capital firm | Seoul, South Korea | 1 | 3% | 1 | ImpriMed |
| 4 | Plug and Play | Startup accelerator | Sunnyvale, United States | 1 | 3% | 1 | ImpriMed |
| 5 | Pear VC | Venture capital firm | Menlo Park, United States | 1 | 3% | 1 | ImpriMed |
| 6 | NFX | Startup accelerator | San Francisco, United States | 1 | 3% | 1 | TwoStep Therapeutics |
| 7 | 2048 Ventures | Venture capital firm | New York, United States | 1 | 3% | 1 | TwoStep Therapeutics |
| 8 | Alexandria Venture Investments | Venture capital firm | Pasadena, United States | 1 | 3% | 1 | TwoStep Therapeutics |
| 9 | GC&H Investments | Corporate venture arm | San Francisco, United States | 1 | 3% | 1 | TwoStep Therapeutics |
| 10 | Jazz Venture Partners | Venture capital firm | San Francisco, United States | 1 | 3% | 1 | Transcripta Bio |
| 11 | BlueYard Capital | Venture capital firm | Berlin, Germany | 1 | 3% | 1 | Transcripta Bio |
| 12 | Matter Venture Partners | Startup accelerator | Manhattan Beach, United States | 1 | 3% | ||
| 13 | S32 | Venture capital firm | San Diego, United States | 1 | 3% | ||
| 14 | Obvious Ventures | Venture capital firm | San Francisco, United States | 1 | 3% | ||
| 15 | Andreessen Horowitz | Venture capital firm | Menlo Park, United States | 1 | 3% |
Table 3. Biotech startups that raised Series A in Palo Alto, United States: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Sectors
| Sectors | Companies | Share | Total raised |
|---|---|---|---|
| Health care | 29 | 85% | $1.5B |
| Software | 10 | 29% | $184.7M |
| Artificial intelligence | 5 | 15% | $93.0M |
| Hardware | 1 | 3% | $21.5M |
| Fintech | 1 | 3% | $11.5M |
| Cybersecurity | 1 | 3% | $11.5M |
Table 4. Biotech startups that raised Series A in Palo Alto, United States by sector. Source: FundingWatcher. Data as of 16 November 2026.
Funding stage
| Funding stage | Companies | Share | Median last round |
|---|---|---|---|
| Series A | 34 | 100% | $24.0M |
Table 5. Biotech startups that raised Series A in Palo Alto, United States by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Rounds by month
| Rounds by month | Companies | Share | Raised |
|---|---|---|---|
| September 2026 | 2 | 25% | $72.5M |
| July 2026 | 1 | 12% | $24.0M |
| June 2026 | 1 | 12% | $40.0M |
| May 2026 | 2 | 25% | $46.0M |
| March 2026 | 1 | 12% | $25.0M |
| January 2026 | 1 | 12% | $200.0M |
Table 6. Biotech startups that raised Series A in Palo Alto, United States: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most recent round by year
| Most recent round by year | Companies | Share | Raised |
|---|---|---|---|
| 2026 | 8 | 24% | $407.5M |
| 2025 | 2 | 6% | $82.0M |
| 2023 | 5 | 15% | $288.5M |
| 2022 | 4 | 12% | $183.8M |
| 2021 | 4 | 12% | $224.0M |
| 2020 | 2 | 6% | $30.7M |
Table 7. Biotech startups that raised Series A in Palo Alto, United States by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Founding year
| Founding year | Companies | Share |
|---|---|---|
| 2023 or later | 4 | 12% |
| 2020 to 2022 | 13 | 38% |
| 2015 to 2019 | 8 | 24% |
| 2010 to 2014 | 5 | 15% |
| Before 2010 | 4 | 12% |
Table 8. Biotech startups that raised Series A in Palo Alto, United States by founding year. Source: FundingWatcher. Data as of 16 November 2026.
Team size
| Team size | Companies | Share |
|---|---|---|
| 1 to 10 | 5 | 16% |
| 11 to 50 | 22 | 69% |
| 51 to 100 | 3 | 9% |
| 101 to 250 | 2 | 6% |
Table 9. Biotech startups that raised Series A in Palo Alto, United States by headcount. Source: FundingWatcher. Data as of 16 November 2026.
Method
- A company is on this list when Biotech is one of its sectors and its most recent funding round is Series A and its headquarters is in Palo Alto, United States. On 16 November 2026 that is 34 companies.
- Stage, round, amount and date are those of the company's most recent funding round. Amounts are in US dollars as the source records them.
- The table prints the 3 newest rounds whose row is complete: a one-sentence description, a city, a named fund and an amount. The CSV carries all 34 rows: 2 have no round amount, 0 no city and 1 no website. The CSV carries domain, website, LinkedIn and the cached description sentence where present.
Sources, fields and exclusions of both files: Method.
Questions
- How many biotech startups in Palo Alto, United States whose last round is Series A are on the list?
- 34, in the file dated 16 November 2026. 8 of them closed their most recent round in the last 12 months.
- What does the CSV contain?
- One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
- How much does the list cost?
- $29 one-time for all 34 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
- What arrives after payment?
- At once: the CSV download link, on the page after payment and by mail.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.